What is the 13F Pro Quality Score for NUTX?

13F Pro ranks Nutex Health Inc. (NUTX) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View NUTX's current score at https://13fpro.ai/research/NUTX (free sign-up required for the full ranking).

Which hedge funds own the most NUTX stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of NUTX include BlackRock,, Pertento Partners LLP, VANGUARD CAPITAL MANAGEMENT. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/NUTX as soon as new 13F filings post.

Where does 13F Pro source NUTX data?

All Nutex Health Inc. fundamentals and ownership data come directly from SEC EDGAR. Nutex Health Inc. files with the SEC under CIK 1479681. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is NUTX in?

Nutex Health Inc. (NUTX) is classified in the Industrials sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/industrials.

What drives NUTX's revenue?

Per Nutex Health Inc.'s latest 10-Q filed with the SEC on 2026-04-30, the biggest revenue drivers are: Hospital division ($207.6M, +1.8% YoY); Population health management division ($8.9M, +13.6% YoY). Figures are extracted from the filing text and machine-verified against the document. Full breakdown at https://13fpro.ai/research/NUTX.

What are NUTX's largest expenses?

Nutex Health Inc.'s latest 10-Q reports these as the largest expense items: Arbitration costs (included in contract services) ($46.1M, +75% YoY); Payroll ($41.4M, +18.8% YoY). Sourced directly from SEC EDGAR filing text for Q1 FY2026 (quarter ended March 31, 2026).

How often is NUTX research updated on 13F Pro?

NUTX's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Nutex Health Inc.(NUTX)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Industrials →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1479681 NUTX stock profile & AI dashboard →

13F Pro Quality Score

74.0/100

Rank #169 of 2,879 stocksTOP 10%

View Industrials peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

95.5/100

Profitability

78.9/100

Balance Sheet

89.2/100

Earnings Quality

30.0/100

Free Cash Flow

83.6/100

Institutional Flow

75.4/100

Revenue Scale

48.2/100

Dilution Risk

14.6/100

NUTX Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Nutex Health Inc. (NUTX), a Industrials sector company. 13F Pro's AI-powered ranking engine scores NUTX at 74.0/100 on a 32-signal composite quality model, placing it at rank #169 of 2,879 stocks — the top 10% of the AI-ranked universe. NUTX scores in the top quartile across revenue growth (95.5), balance sheet strength (89.2), free cash flow (83.6). Areas of concern include earnings quality (30.0), which score below median versus the broader universe. Shareholder dilution risk is elevated at 14.6/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Nutex Health Inc. reports quarterly revenue of $216.5M, net income of $46.8M, an operating margin of 37.5%. Top institutional holders of NUTX by reported 13-F value include BlackRock,, Pertento Partners LLP, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. NUTX trades on the Nasdaq exchange and files with the SEC under CIK 1479681. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate NUTX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Nutex Health Inc. directly from SEC EDGAR. Nutex Health Inc.'s 13F Pro composite quality score has ranged between 8 and 80 since 2022, currently 74.0 — a stable long-term trajectory across 50 quarterly and live scoring snapshots.

✦

Fun facts about Nutex Health Inc.

Quirks, history, and lore behind NUTX — the kind of stuff that makes a stock memorable.

1
The Basics
A small-cap U.S. company operating in the healthcare facilities space, listed on Nasdaq, and headquartered in Texas.
2
The Numbers
Revenue in the hundreds of millions of dollars, but like many facility operators it has wrestled with thin or negative margins as it works through a growth-heavy build-out phase.
3
The History
Built through acquisition and development of hospital facilities, the company went public via a SPAC merger — the fashionable way to list in the early 2020s.
4
The Secret
Its core business model centers on owning and operating micro-hospitals — small, full-service inpatient facilities designed to serve suburban and underserved communities that big hospital systems ignore.
5
The Lore
The company also has a hospital management division that partners with health systems, effectively letting it collect fees for running other people's hospitals too — a tidy side hustle.
6
The Giveaway
Think tiny hospitals, big ambitions — this Houston-based operator of micro-hospitals across multiple states trades under a ticker that neatly rhymes with "bucks."

▶ Think you know your stocks? Play the Daily Ticker

What's Driving NUTX's Business? Latest 10-Q Breakdown

AI-extracted from Nutex Health Inc.'s 10-Q filed 2026-04-30 — Q1 FY2026 (quarter ended March 31, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.

Biggest Revenue Drivers

Total revenue: $216.5M+2.2% YoY

Hospital division$207.6M+1.8% YoY

Increase in cash collections and billable visits slightly offset by decrease in net revenue per visit; same-hospital revenue +0.2%.

Population health management division$8.9M+13.6% YoY

Growth principally through addition of new independent physician associations.

Largest Expense Items

Arbitration costs (included in contract services)$46.1M+75% YoY

Total cost of arbitration for hospital and professional services increased from $26.3M; includes IDR vendor fees and CIDRE payments.

Payroll$41.4M+18.8% YoY

Higher payroll driven by increased operations and staffing for population health management division.

Watch Items from the Filing

Arbitration costs escalated to $46.1M in Q1 2026 from $26.3M in Q1 2025 (+75%), representing 21% of hospital division revenue. Further cost increases could materially pressure margins if revenue growth stalls.
Litigation risk: ABQ Plaintiffs dispute reverse stock split adjustment to Parent Stock Price Floor, potentially forcing issuance of significantly higher shares; trial set September 21, 2026. Eight hospitals' earn-out shares already total ~1.37M shares (19.8% of outstanding).
Securities class action and derivative litigation pending regarding alleged misstatements about IDR vendor conduct and internal controls; motion to dismiss filed April 3, 2026. Company unable to estimate financial exposure.
Same-hospital revenue growth of only 0.2% while total visits grew 3.1%, indicating that new facility openings (2 in 2025) are driving growth, not same-store strength. Net revenue per visit declined YoY.

AI-extracted and verified against SEC EDGAR filing text. Not investment advice.

Read the full 10-Q on SEC EDGAR →Share on X

Revenue

Q1 2026

$216.5M

Net Income

Q1 2026

$46.8M

Free Cash Flow

Q1 2026

$74.3M

Operating Margin

Q1 2026

37.5%

D/E Ratio

Q1 2026

0.12

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+253.4% YoY

$875.3MFY 2025

FY21 $331.5MFY22 $219.3MFY23 $247.6MFY25 $875.3M

Net Income

+254.6% YoY

$70.8MFY 2025

FY21 $132.6MFY22 $-424.8MFY23 $-45.8MFY25 $70.8M

Operating Income

+967.5% YoY

$275.6MFY 2025

FY21 $170.3MFY22 $-406.6MFY23 $-31.8MFY25 $275.6M

EPS (Diluted)

+655100.0% YoY

$10.48FY 2025

FY21 $0.00FY22 $-0.01FY23 $-0.00FY25 $10.48

Total Assets

+130.6% YoY

$918.5MFY 2025

FY21 $394.7MFY22 $431.8MFY23 $398.2MFY25 $918.5M

Total Debt

+14.5% YoY

$42.5MFY 2025

FY21 $178.3MFY22 $35.6MFY23 $37.1MFY25 $42.5M

Op. Cash Flow

+19639.5% YoY

$248.1MFY 2025

FY21 $173.4MFY22 $50.6MFY23 $1.3MFY25 $248.1M

Metric	FY 2025	FY 2023	FY 2022	FY 2021	FY 2016	FY 2015
Revenue	$875.3M +253.4%	$247.6M +12.9%	$219.3M -33.9%	$331.5M	$0.00 -100.0%	$474.7K
Net Income	$70.8M +254.6%	$-45.8M +89.2%	$-424.8M -420.4%	$132.6M +1884.0%	$-7.4M -8968.1%	$83.8K
Operating Income	$275.6M +967.5%	$-31.8M +92.2%	$-406.6M -338.8%	$170.3M +38055.1%	$-448.6K +15.8%	$-533.0K
EPS (Diluted)	$10.48 +655100.0%	$-0.00 +89.3%	$-0.01 -406.1%	$0.00	—	—
Total Assets	$918.5M +130.6%	$398.2M -7.8%	$431.8M +9.4%	$394.7M +77155.9%	$510.8K -93.3%	$7.6M
Total Debt	$42.5M +14.5%	$37.1M +4.3%	$35.6M -80.0%	$178.3M	—	—
Operating Cash Flow	$248.1M +19639.5%	$1.3M -97.5%	$50.6M -70.8%	$173.4M +63345.1%	$-274.2K -710.6%	$44.9K

AI Insight: NUTX Financial Trends

Operating cash flow surged to $76M in Q1 2026 while equity nearly doubled year-over-year to $346M, signaling a dramatically strengthened balance sheet.

• Revenue jumped from ~$77M average in Q2–Q3 2024 to $216M in Q1 2026, reflecting a step-change in scale after Q4 2024.

• Equity expanded from $63M in Q2 2024 to $346M in Q1 2026, a more than 5x increase over six quarters.

• Operating cash flow recovered strongly to $76M–$100M in Q4 2025 and Q1 2026 after near-zero in Q4 2024.

• Net income remains volatile, swinging from $-11M in Q2 2025 to $55M in Q3 2025 and $12M in Q4 2025.

⚠ Operating income dropped sharply to $31M in Q4 2025 from $130M in Q3 2025 — revenue also fell $116M sequentially.

⚠ Total debt crept up from $35M in Q1 2025 to $44M in Q3 2025, though still modest relative to $346M equity.

⚠ Persistent net income volatility despite rising operating income suggests significant non-operating or one-time items warrant scrutiny.

AI Insight: NUTX Ratio Trends

Leverage has collapsed from 0.62 to 0.12 D/E while Q1 2026 ROIC hit 83.9%, signaling a dramatically strengthened capital structure.

• D/E ratio fell from 0.62 in Q3 2024 to 0.12 in Q1 2026, a near-five-fold reduction in leverage over five quarters.

• ROIC surged to 83.9% in Q1 2026 from 21.3% in Q2 2024, reflecting sharply higher returns on invested capital.

• Operating margin is highly volatile, swinging from 7.0% in Q2 2024 to 48.7% in Q3 2025 and back to 20.4% in Q4 2025.

• Net profit margin turned solidly positive in Q1 2026 at 21.6%, recovering from losses of -11.2% in Q3 2024 and -4.6% in Q2 2025.

⚠ Quarter-to-quarter margin swings are extreme — two of the last five quarters posted negative NPM, flagging recurring earnings volatility.

⚠ ROIC data is missing for Q4 2024, Q1 2025, and Q3 2025, limiting visibility into capital efficiency trends across periods.

⚠ TTM OpMargin of 32.4% trails Q1 2026's 37.5%, suggesting recent quarterly improvement may not yet be fully reflected in trailing results.

Get alerted when NUTX's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Nutex Health Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of NUTX

BlackRock, Inc.
$36.1M379,355 sh
Pertento Partners LLP
$35.5M373,970 sh
VANGUARD CAPITAL MANAGEMENT LLC
$20.8M219,131 sh
AMERICAN CENTURY COMPANIES INC
$19.3M203,450 sh
Topline Capital Management, LLC
$16.9M177,800 sh
STATE STREET CORP
$11.7M123,177 sh
GEODE CAPITAL MANAGEMENT, LLC
$11.6M122,113 sh
MILLENNIUM MANAGEMENT LLC
$8.5M89,571 sh
UBS Group AG
$6.6M69,570 sh
WINMILL & CO. INC
$6.2M65,350 sh

Fund	Value	Shares
BlackRock, Inc.	$36.1M	379,355
Pertento Partners LLP	$35.5M	373,970
VANGUARD CAPITAL MANAGEMENT LLC	$20.8M	219,131
AMERICAN CENTURY COMPANIES INC	$19.3M	203,450
Topline Capital Management, LLC	$16.9M	177,800
STATE STREET CORP	$11.7M	123,177
GEODE CAPITAL MANAGEMENT, LLC	$11.6M	122,113
MILLENNIUM MANAGEMENT LLC	$8.5M	89,571
UBS Group AG	$6.6M	69,570
WINMILL & CO. INC	$6.2M	65,350

More Industrials Companies

View all Industrials →

AADX

Applied Aerospace & Defense, Inc.

AAL

American Airlines Group Inc.

AAON

AAON, INC.

ABM

ABM INDUSTRIES INC /DE/

ACA

Arcosa, Inc.

ACHR

Archer Aviation Inc.

ACLS

AXCELIS TECHNOLOGIES INC

ACMR

ACM Research, Inc.

Put NUTX on your watchlist

Track score changes the day Nutex Health Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is NUTX a good stock to buy?

13F Pro's AI-powered analysis of Nutex Health Inc. (NUTX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Industrials sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for NUTX are available on the NUTX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own NUTX?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling NUTX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Nutex Health Inc.'s investment landscape.